License and Collaboration Agreement with ApolloBio Corp to Develop and Commercialize VGX-3100 in Greater China
|Inovio Pharmaceuticals Inc.|
Inovio will immediately receive $23 million in upfront payment; an additional $20 million in future regulatory milestone payments and double-digit tiered royalties on future sales.
|Global M&A Offices||
Hollyhigh International Capital (Global M&A China)
|Global M&A Advisory||Advisor to the seller|